( MENAFN - 3BL) GREENFIELD, Ind., May 28, 2024 /3BL/ - Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S.
Food and Drug Administration (FDA) has completed its comprehensive, multi-year review of Bovaer® (3-NOP), a first-in-class methane-reducing feed ingredient, and determined the product meets safety and efficacy requirements for use in lactating dairy cattle. “This monumental announcement has the ability to accelerate the opportunity for climate-neutral dairy farming while creating a new revenue stream for dairy farmers across the country,” said Jeff Simmons, President and CEO, Elanco Animal Health.“We appreciate FDA's commitment to maintaining high standards for science-based review, while balancing the need to quickly bring solutions to the market.
Bovaer represents another example of Elanco being a partner of choice in animal health, where the capabilities of our talented R&D, regulatory and commercial teams are delivering significant value. Simmons continued:“As global temperatures breach new thresholds, consumers demand more sustainable products and the farm economy battles profitability challenges, we are excited to bring Bovaer to the market as a potential solution. Bovaer will create value for farmers, while helping food companies meet consumer demands and deliver on their sustainability commitments.
As animal, human and now environmental health continue to converge, Bovaer is one of the most significant innovations that considers this .
